Patent Application
20230265101
The present disclosure relates to methods for preparing ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone, a compound useful for inhibiting Janus Kinases (JAKs). The disclosure also relates to intermediates for preparing said compound.
((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone has the chemical formula C18H21F2N7O and the following structural formula:
A prior synthesis of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone is described in commonly assigned U.S. Pat. No. 9,663,526, the contents of which are incorporated herein by reference in its entirety. The crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone free base, is useful as an inhibitor of protein kinases, such as the enzyme Janus Kinase and as such is useful therapeutically as an immunosuppressive agent for organ transplants, xenotransplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other indications where immunosuppression would be desirable.
Accordingly, it is desirable to provide more efficient methods of manufacturing ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone and its p-toluenesulfonic acid salt, affording the product in higher yield and superior purity.
The present disclosure provides a method for preparing a compound of formula I:
comprising (a) (i) preparing a salt from a compound having the structure:
and a base having the structure:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; or,
wherein R is selected from the group consisting of C6-C12 aryl and C4-C0 heteroaryl, wherein said C6-C12 aryl and C4-C9 heteroaryl are optionally substituted with a C1-C6 alkyl, —S(═O)—R0, —S(═O)2—R0, cyano, nitro, C1-C6 alkoxy, or halo, where R0 is C1-C6 alkyl;
under conditions suitable to form the compound of formula I.
The present disclosure will be further understood from the following description given by way of example only. The present disclosure is directed to methods for the preparation of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone and novel intermediates thereto. While the present disclosure is not so limited, an appreciation of various aspects of the disclosure will be gained through the following discussion and the examples.
The term “alkyl,” as used herein, means a straight or branched chain monovalent hydrocarbon group of formula —CnH(2n+1). Non-limiting examples include methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl and hexyl.
The term “alkoxy,” as used herein, means an alkyl substituent attached through an oxygen atom. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexyloxy.
The term “benzyl,” as used herein, means a phenylmethyl group.
The term “aryl,” as used herein, means a 6 to 8-membered monocyclic or 6 to 12-membered bicyclic carbocycle which is aromatic or partially unsaturated, said carbocycle being optionally substituted by one or more groups R. Examples include phenyl or naphthalenyl.
The term “heteroaryl,” as used herein, refers to a monocyclic or bicyclic aromatic hydrocarbon containing from 5 to 10 ring atoms in which at least one of the ring carbon atoms has been replaced with a heteroatom selected from oxygen, nitrogen and sulfur. Such a heteroaryl group may be attached through a ring carbon atom or, where valency permits, through a ring nitrogen atom. Common examples of 10-membered heteroaryl groups include quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5-naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl and pyrimido[4,5-d]pyrimidinyl.
The term “halogen,” or “halo,” as used herein, refers to fluoride, chloride, bromide, or iodide.
The term “amino,” as used herein, refers to —NH2.
When a substituent is defined as a combination of two groups (e.g., alkoxyalkyl) the moiety concerned is always attached through the second of the two groups named (in this case alkyl). Thus, for example, ethoxymethyl corresponds to CH3CH2—O—CH2—.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure have the meanings that are commonly understood by those of ordinary skill in the art.
If substituents are described as being “independently selected” from a group, each substituent is selected independent of the other. Each substituent therefore may be identical to or different from the other substituent(s).
According to a first aspect of the disclosure, there is provided a method for preparing a compound of formula I:
comprising (a) (i) preparing a salt from a compound having the structure:
and a base having the structure:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; or,
(ii) preparing an activated ester having the structure:
wherein R is selected from the group consisting of C6-C12 aryl and C4-C0 heteroaryl, wherein said C6-C12 aryl and C4-C9 heteroaryl are optionally substituted with a C1-C6 alkyl, —S(═O)—R0, —S(═O)2—R0, cyano, nitro, C1-C6 alkoxy, or halo, where R0 is C1-C6 alkyl;
(b) reacting said activated ester or said salt with a compound of formula IV:
under conditions suitable to form the compound of formula I.
Described below are a number of embodiments (E) of this first aspect of the disclosure, where for convenience E1 is identical thereto.
comprising (a) (i) preparing a salt from a compound having the structure:
and a base having the structure:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; or,
wherein R is selected from the group consisting of C6-C12 aryl and C4-C0 heteroaryl, wherein said C6-C12 aryl and C4-C9 heteroaryl are optionally substituted with a C1-C6 alkyl, —S(═O)—R0, —S(═O)2—R0, cyano, nitro, C1-C6 alkoxy, or halo, where R0 is C1-C6 alkyl;
(b) reacting said activated ester or said salt with a compound of formula IV:
under suitable conditions to form the compound of formula I:
and,
(c) treating said compound with p-toluenesulfonic acid under suitable conditions to afford the p-toluenesulfonic acid salt of the formula IA:
comprising (a) preparing a carboxylic acid having the structure:
and,
(b) reacting said carboxylic acid with a compound having the structure:
under suitable conditions to form the salt of formula II.
wherein R5 is C1-C6 alkyl, C3-C6 cycloalkyl, benzyl, C6-C12 aryl, or C4-C9 heteroaryl with an ester compound having the structure:
wherein R6 is C1-C5 alkyl, benzyl, C6-C12 aryl, or C4-C9 heteroaryl.
wherein R7 is C2-C6 alkyl, C3-C6 cycloalkyl, benzyl, C6-C12 aryl, and C4-C9 heteroaryl with an ester compound having the structure:
wherein R6 is C1-C5 alkyl, benzyl, C6-C12 aryl, or C4-C9 heteroaryl under suitable conditions to form an intermediate having the structure:
(b) treating the intermediate generated in step (a) with a Lewis acid selected from the group consisting of FeCl3 and AlCl3 under suitable conditions to form the alcohol compound having the structure:
and,
(c) reacting said alcohol compound with an oxidizing agent under suitable conditions to form the carboxylic acid.
wherein R7 is C4-C6 alkyl C1-C6 alkyl, C3-C6 cycloalkyl, benzyl, C6-C12 aryl, or C4-C9 heteroaryl with an ester compound having the structure:
wherein R6 is selected from the group consisting of C1-C5 alkyl, benzyl, C6-C12 aryl, and C4-C9 heteroaryl under suitable conditions to form an intermediate having the structure:
(b) treating the intermediate generated in step (a) with a base selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, cesium carbonate, lithium carbonate, potassium carbonate, ammonium sodium carbonate, ammonium carbonate, lithium bicarbonate, sodium bicarbonate, potassium carbonate, metal or ammonium carboxylates, mono-, and di- and tri-basic metal phosphates, under suitable conditions to form an alcoholic compound having the structure:
(c) reacting said alcoholic compound with an oxidizing agent selected from the group consisting of periodate, chromate, peroxide, sodium hypochlorite and potassium hypochlorite under suitable conditions to provide the carboxylic acid.
or a salt thereof, or solvate thereof, wherein R8 is optionally substituted arylmethylene, and said salt is a dihydrochloride or dihydrobromide salt.
or a salt thereof, or solvate thereof, wherein R8 is optionally substituted arylmethylene, and said salt is a dihydrochloride or dihydrobromide salt, comprising the step of reacting a compound having the structure:
wherein R8 is optionally substituted arylmethylene, and X is methoxy, ethoxy, Cl, Br or I, with a compound having the structure:
under conditions suitable to form the compound of formula III.
is prepared under suitable conditions from a compound of formula III:
or a salt thereof, or solvate thereof, wherein R8 is optionally substituted arylmethylene, and said salt is a dihydrochloride or dihydrobromide salt.
is prepared under suitable conditions from a compound of formula III:
or a salt thereof, or solvate thereof, wherein R8 is optionally substituted arylmethylene, and said salt is a dihydrochloride or dihydrobromide salt.
prepared by a process comprising (a) (i) preparing a salt from a compound having the structure:
and a base having the structure:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; or,
(ii) preparing an activated ester having the structure:
wherein R is selected from the group consisting of C6-C12 aryl and C4-C0 heteroaryl, wherein said C6-C12 aryl and C4-C9 heteroaryl are optionally substituted with a C1-C6 alkyl, —S(═O)—R0, —S(═O)2—R0, cyano, nitro, C1-C6 alkoxy, or halo, where R0 is C1-C6 alkyl;
(b) reacting said activated ester or said salt with a compound of formula IV:
under conditions suitable to form the compound of formula I.
is prepared under suitable conditions from a compound of formula III:
or a salt thereof, wherein R8 is optionally substituted arylmethylene, and said salt is a dihydrochloride or dihydrobromide salt.
prepared by a process comprising (a) (i) preparing a salt from a compound having the structure:
and a base having the structure:
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; or,
(ii) preparing an activated ester having the structure:
wherein R is selected from the group consisting of C6-C12 aryl and C4-C0 heteroaryl, wherein said C6-C12 aryl and C4-C9 heteroaryl are optionally substituted with a C1-C6 alkyl, —S(═O)—R0, —S(═O)2—R0, cyano, nitro, C1-C6 alkoxy, or halo, where R0 is C1-C6 alkyl;
(b) reacting said activated ester or said salt with a compound of formula IV:
under suitable conditions to form the compound of formula I:
and,
(c) treating said compound with p-toluenesulfonic acid under suitable conditions to afford the p-toluenesulfonic acid salt of formula IA:
wherein A is C1-C6 alkyl, comprising (a) reacting a compound having the structure:
wherein X is halo, with acetamide in the presence of catalyst under suitable conditions to prepare a protected compound having the formula:
and (b) treating said protected compound under suitable conditions to form the compound having the structure:
The following schemes and written descriptions provide general details regarding the preparation of the compound of formula I, or the p-toluenesulfonic acid salt thereof. In particular, the compound or salt can be prepared by the procedures described by reference to the Schemes that follow, or by the specific methods described in the Examples, or by similar processes to either.
The skilled person will appreciate that the experimental conditions set forth in the schemes that follow are illustrative of suitable conditions for effecting the transformations shown, and that it may be necessary or desirable to vary the precise conditions employed for the preparation of the compound of formula I, or the p-toluenesulfonic acid salt thereof.
In addition, the skilled person will appreciate that it may be necessary or desirable at any stage in the synthesis of the compound of formula I, or the p-toluenesulfonic acid salt thereof, to protect one or more sensitive groups, so as to prevent undesirable side reactions. In particular, it may be necessary or desirable to protect amino or carboxylic acid groups. The protecting groups used in the preparation of the compounds of the disclosure may be used in conventional manner. See, for example, those described in ‘Greene's Protective Groups in Organic Synthesis’ by Theodora W Greene and Peter G M Wuts, third edition, (John Wiley and Sons, 1999), in particular chapters 7 (“Protection for the Amino Group”) and 5 (“Protection for the Carboxyl Group”), incorporated herein by reference, which also describes methods for the removal of such groups.
Accordingly, the compound of formula I, or the p-toluenesulfonic acid salt thereof can be prepared by the procedures described in the general methods presented below or by routine modifications thereof. The present disclosure also encompasses any one or more of these processes for preparing the derivatives of formula I, in addition to any novel intermediates used therein. The person skilled in the art will appreciate that the following reactions may be heated thermally or under microwave irradiation. It will be further appreciated that it may be necessary or desirable to carry out the transformations in a different order from that described in the schemes, or to modify one or more of the transformations, to provide the desired compound of the disclosure.
One skilled in the art will also recognize that some compounds of the disclosure are chiral and thus may be prepared as racemic or scalemic mixtures of enantiomers. Several methods are available and are well known to those skilled in the art for the separation of enantiomers. A preferred method for the routine separation enantiomers is supercritical fluid chromatography employing a chiral stationary phase.
The compound of formula I or the p-toluenesulfonic acid salt thereof, may be prepared from compounds A-1, A-2 and C-3, as illustrated by Scheme A. Compounds of formulae A-1, A-2 and C-3 are commercially available or may be synthesized by those skilled in the art according to the literature or preparations described herein. For these purposes, PG is a protecting group, as known by those so skilled in the art, for example, and may be tert-butoxycarbonyl. Compounds of formula A-3 may be prepared from compounds of formulae A-1 and A-2 according to process step (i), an aromatic nucleophilic substitution reaction in the presence of an organic base. Preferred conditions comprise triethylamine in methanol at from 0° C. to room temperature. This reaction (i) can be run in various solvents, including methanol, 2-MeTHF, DMSO, THF or combinations thereof. Organic bases used in the reaction include such bases as tertiary amines, DBN, guanidine, amidine, NMI, potassium carbonate, potassium phosphate, lithium hydroxide, lithium methoxide, and lithium carbonate.
Compounds of formula A-5 may be prepared from compounds of formula A-3 according to process steps (ii) and (iii), a nucleophilic substitution reaction with compounds of formula C-3 under either Buchwald-Hartwig cross coupling conditions or mediated by acid and elevated temperatures followed by a deprotection reaction mediated by either an inorganic or organic acid. Typical Buchwald-Hartwig conditions comprise a suitable palladium catalyst with a suitable chelating phosphine ligand with an inorganic base in a suitable organic solvent at elevated temperatures either thermally or under microwave irradiation. Preferred conditions comprise either a) palladium(II) acetate and 2-dicyclohexylphosphino- 2′,4′,6′-triisopropylbiphenyl or xantphos with sodium tert-butoxide, b) potassium phosphate or cesium carbonate in DMA at from 120-140° C. under microwave irradiation or c) BrettPhos Pd G3 with cesium carbonate as base and either DMA or dioxane as solvent at 40° C. Typical acidic conditions comprise a suitable inorganic acid in a suitable alcoholic solvent at elevated temperatures either thermally or under microwave irradiation. Preferred conditions comprise concentrated hydrochloric acid in iso-propanol at 140° C. under microwave irradiation. Alternatively, the deprotection occurs in situ during process step (ii). Compounds of formula A-6 may be prepared from compounds of formula A-5 according to process step (iv), an amide bond formation reaction with compounds of formula BC(O)X, wherein X may be chloro, hydroxy, a suitable leaving group or anhydride (e.g., (S)-2,2-Difluorocyclopropane-1-carboxylic acid). Wherein compounds of formula BC(O)X are acid chlorides (e.g., Example 2), preferred conditions comprise triethylamine in dichloromethane at room temperature. Wherein compounds of formula BC(O)X are carboxylic acids (e.g., Example 1) activation of the carboxylic acid using a suitable organic base and a suitable coupling agent is employed. Preferred conditions comprise DIPEA or triethylamine with HATU in dichloromethane or DMF at room temperature. Many other amide bond-forming reagents work for this transformation including the acid chloride, CDI/HOPO, T3P, EDCI, and DPPCI. Trifluoroethanol is a good alternative solvent.
Alternatively, the compound of formula I, or the p-toluenesulfonic acid salt thereof, may be prepared from compounds A-3 and C-3, as illustrated by Scheme B. Compounds of formula A-3 are prepared as described in Scheme A. Compounds of formula C-3 are commercially available or may be synthesized by those skilled in the art according to the literature or preparations described herein. Compounds of formula B-1 may be prepared from compounds of formula A-3 according to process step (i) a deprotection reaction mediated by either an inorganic or organic acid in a suitable organic solvent. Preferred conditions comprise hydrochloric acid or TFA in dioxane or DCM. This reaction can be run in trifluoroethanol. Other acids can also be used such as acetic acid, phosphoric acid, citric, L-tartaric, methane sulfonic acid, and sulfuric acid.
Compounds of formula B-2 may be prepared from compounds of formulae B-1 and BC(O)X according to process step (ii), an amide bond formation reaction as described in Scheme A. Compounds of formula A-6 may be prepared from compounds of formula B-2 according to process step (iii), a nucleophilic substitution reaction with compounds of formula C-3 under either Buchwald-Hartwig cross coupling conditions or mediated by acid and high temperatures as described in Scheme A.
Compounds of formula C-3 employed in Scheme A and Scheme B may be prepared from compounds of formula C-1, as illustrated in Scheme C. The compound of formula C-1 is commercially available or may be synthesized by those skilled in the art according to the literature or preparations described herein. Compounds of formula C-2 may be prepared from compounds of formula C-1 according to process step (i) an alkylation reaction with an appropriately substituted alkyl halide of the formula AX where X is Cl, Br or I in the presence of an inorganic or organic base and a solvent such as DMF, or an addition reaction to an epoxide in the presence of an inorganic or organic base. Compounds of formula C-3 may be prepared from compounds of formula C-2 according to process step (ii) a reduction typically performed in the presence of a metal catalyst such as palladium or nickel, hydrogen gas at a pressure of 1-50 atmospheres, and a protic solvent such as methanol.
The following non-limiting Preparations and Examples illustrate the preparation of compounds and salts of the present disclosure. In the Examples and Preparations that are set out below, and in the aforementioned Schemes, the following abbreviations, definitions and analytical procedures may be referred to. Other abbreviations common in the art may also be used. Compounds of the present disclosure were named using ChemDraw Professional™ version 18.0 (Perkin Elmer) or were given names which appeared to be consistent with IUPAC nomenclature.
1H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g., s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used for common NMR solvents: CD3CN, deuteroacetonitrile; CDCl3, deuterochloroform; DMSO-d6, deuterodimethylsulfoxide; and CD3OD, deuteromethanol. Where appropriate, tautomers may be recorded within the NMR data; and some exchangeable protons may not be visible. Some resonances in the NMR spectrum appear as complex multiplets because the isolate is a mixture of two conformers.
Mass spectra were recorded using electron impact ionization (EI), electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). The observed ions are reported as MS m/z and may be positive ions of the compound [M]+, compound plus a proton [MH]+, or compound plus a sodium ion [MNa]+. In some cases the only observed ions may be fragment ions reported as [MH-(fragment lost)]+. Where relevant, the reported ions are assigned for isotopes of chlorine (35Cl and/or 37Cl), bromine (79Br and/or 81Br) and tin (120Sn).
Wherein TLC, chromatography or HPLC has been used to purify compounds, one skilled in the art may choose any appropriate solvent or combination of solvents to purify the desired compound. Chromatographic separations (excluding HPLC) were carried out using silica gel adsorbent unless otherwise noted.
All reactions were carried out using continuous stirring under an atmosphere of nitrogen or argon gas unless otherwise noted. In some cases, reactions were purged with nitrogen or argon gas prior to the start of the reaction. In these cases, the nitrogen or argon gas was bubbled through the liquid phase of the mixture for the approximate specified time. Solvents used were commercial anhydrous grades. All starting materials were commercially available products. In some cases, the Chemical Abstracts Service® (CAS) identification number is provided to assist with clarity. It will be apparent to one skilled in the art that the word “concentrated” as used herein generally refers to the practice of evaporation of solvent under reduced pressure, typically accomplished using a rotary evaporator.
The following abbreviations are used herein:
Preparation 1: 4-((1R,5S)-8-Benzyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine.
(1R,5S)-8-Benzyl-3,8-diazabicyclo[3.2.1]octane (5.0 g, 18 mmol) is dissolved in methanol (50 mL) and 2-methyl tetrahydrofuran (25 mL) and the solution is cooled to 0° C. 2,4-Dichloropyrimidine (2.99 g, 20 mmol) is added. N,N-diisopropylethylamine (10.8 mL, 62 mmol) is added. The reaction is stirred until complete. The solution is warmed to room temperature. Water (50 mL) is added and the reaction heated to 55° C. Reaction may be seeded. Reaction is cooled and the product is isolated by filtration and dried under vacuum. (1R,5S)-8-Benzyl-3-(2-chloropyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane (5.3 g) is isolated as a crystalline white solid. 1H NMR (400 MHz, DMSO) δ 8.06 (d, J=6.1 Hz, 1H), 7.59-6.97 (m, 5 H), 6.72 (d, J=6.2 Hz, 1H), 4.15 (s, 1H), 3.56 (s, 3 H), 3.26 (s, 2 H), 3.07 (s, 2 H), 1.99 (dd, J 32 8.8, 4.2 Hz, 2 H), 1.49 (t, J=7.2 Hz, 2 H). 13C NMR (101 MHz, DMSO) δ 164.2, 159.8, 157.5, 139.8, 128.9, 128.6, 127.3, 102.7, 57.9, 56.0, 25.6. mp: 117.6° C. Alternate Procedure: (1R,5S)-8-Benzyl-3,8-diazabicyclo[3.2.1] dihydrochloride (5 g, 18.17 mmol) and methanol (25 mL) are charged to a 50 mL reactor. N,N-diisopropylethylamine (9.8 mL, 56 mmol, 3.1 equiv) was added to the slurry. A solution of 2,4-dichloropyrimidine (2.6 g, 17 mmol, 0.96 equiv) in 2-methyltetrahydrofuran (25 mL) and methanol (5 mL) was added over 30 min. The reaction is stirred until complete and carried directly into the Step 2 procedure.
Preparation 2. 4-((1R,5S)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine.
4-((1R,5S)-8-Benzyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1 H-pyrazol-4-yl)pyrimidin-2-amine (10 g, 23.9 mmol) is combined with water (25 mL) and concentrated hydrochloric acid (3.53 mL, 43.02 mmol, 1.8 equiv). Isopropanol (11 mL) and the pH is adjusted to pH 4 using 1 M aq. HCl solution (4.78 mL, 4.78 mmol, 0.2 equiv). Palladium hydroxide (10%) on carbon (0.3 g) is added and the mixture is heated to 40° C. Hydrogen gas is added under pressure and the mixture stirred until reaction completion. The mixture is cooled to 25 and the catalyst filtered. Water (47 mL) and isopropanol (10 mL) are added. A solution of potassium hydroxide in water (2.5 M, 21 mL, 2.2 equiv) is added. The mixture is then isolated by filtration and washed with water. 4-((1R,5S)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine is isolated as a crystalline white solid. 1H NMR (400 MHz, DMSO) δ 8.77 (s, 1H), 7.86 (d, J=5.9 Hz, 1H), 7.72 (s, 1H), 7.44 (s, 1H), 6.01 (d, J=6.0 Hz, 1H), 3.85 (s, 2H), 3.77 (s, 3H), 3.52-3.46 (m, 2H), 2.93 (d, J=11.9 Hz, 2H), 1.66 (dd, J=8.2, 4.3 Hz, 2H), 1.54 (t, J=6.5 Hz, 2H). 13C NMR (101 MHz, DMSO) 6 164.0, 159.3, 156.6, 130.0, 124.3, 120.3, 94.1, 53.5, 51.3, 39.0, 28.9. mp: 243.2° C.
Preparation 3. (S)-2,2-difluorocyclopropane-1-carboxylic acid 2,2′,2″-nitrilotris(ethan-1-ol) salt.
To a 100 mL reactor was added ACN (50.0 mL) and triethanolamine (12.2 g, 1.0 equivs). This solution was heated to 45° C., and a pre-mixed solution of (S)-2,2-difluorocyclopropane-1-carboxylic acid prepared as describe in preparation 68 of U.S. Pat. No. 9,663,526 (10.1 g, 1.0 equiv) in MTBE (50.0 mL, ˜-20% w/w) was added dropwise over 100 minutes. After addition, the reaction was held at 45° C. for 30 minutes, then cooled to 20° C. at a rate of 0.25° C./min. The mixture was granulated for 30 minutes, then filtered and washed with MTBE (40.0 mL), and dried under vacuum at 50° C. 1H NMR (400 MHz, DMSO-d6) δ 6.85 (s, 4H), 3.61 (t, J=5.7 Hz, 6H), 2.97 (t, J=5.7 Hz, 6H), 2.38 (ddd, J=15.4, 10.8, 7.9 Hz, 1H), 1.84-1.62 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 169.0, 115.9, 113.1 (dd, J=285.9, 281.2 Hz), 113.1, 110.3, 57.4, 56.5, 27.7, 27.6 (dd, J=12.0, 9.2 Hz), 27.6, 27.5, 16.2, 16.1 (t, J=9.8 Hz), 16.0. mp: 82.4° C.
Preparation 4. 2,2-Difluorocyclopropane-1-(S)-carboxylate (R)-N-Benzyl-1-phenylethan-1-aminium salt.
To a 250 mL vessel was added MTBE (134 mL), (S)-2,2-difluorocyclopropane-1-carboxylic acid 2,2′,2″-nitrilotris(ethan-1-ol) salt (20.0 g, 1.0 equiv), and a premixed solution of sulfuric acid (4.3 mL, 1.1 equivs) in water (86.0 mL). The mixture was stirred until all solids dissolved, and then the layers allowed to settle. The layers were separated, and the bottom (aqueous) layer was back-extracted with MTBE (58 mL). The combined organic layers were dried via azeotropic distillation to achieve a final concentration of (S)-2,2-difluorocyclopropane-1-carboxylic acid of -15% (w/w) in MTBE. To this solution was added chiral amine (R)-(+)-N-benzyl-α-methylbenzylamine (13.0 g, 0.85 equivs) dropwise over ˜1 hour. After ˜25% of the amine had been added, the reaction was seeded with previously purified (R)-N-benzyl-1-phenylethan-1-amine (S)-2,2-difluorocyclopropane-1-carboxylate (50 mg, 0.002 equivs). After addition of the amine, the slurry was allowed to granulate, then filtered, and washed with MTBE (12.0 mL) that had been pre-chilled to 10° C., and the solids dried under vacuum at 50° C. The crude solids (10.57 g) were returned to the same vessel and MeCN (35.0 mL) added. The slurry was heated to 80° C. to fully dissolve the solids. The solution was cooled to 22° C. at a rate of 0.2° C./min and allowed to granulate. The product was collected by filtration and washed with MeCN (13.0 mL) before drying under vacuum at 50° C. 1H NMR (400 MHz, DMSO-d6) δ 9.25 (s, 2H), 7.46 (d, J=6.9 Hz, 2H), 7.43-7.24 (m, 9H), 4.00 (q, J=6.7 Hz, 1H), 3.74 (d, J =13.3 Hz, 1H), 3.65 (s, 1H), 2.50-2.39 (m, 1H), 1.90-1.66 (m, 2H), 1.43 (d, J=6.7 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 168.5, 142.4, 137.1, 129.3, 129.0, 128.7, 128.0, 127.9, 127.6, 116.0, 113.2, 113.1 (dd, J=286.1, 281.3 Hz), 110.3, 57.2, 49.8, 27.6, 27.5, 27.5 (dd, J =12.0, 9.3 Hz), 27.4, 22.5, 16.2, 16.1 (t, J=9.8 Hz), 16.07. mp: 138.6° C.
Alternate Procedure: (R)-N-Benzyl-1-phenylethan-1-amine (S)-2,2-difluorocyclopropane-1-carboxylate. To a pre-heated solution of anisole (2.0 kg) at 140° C. was added gradually a solution containing butyl acrylate (200 g), ethyl bromdifluoroacetate (1426 g), and tetrabutylammonium bromide (9.8 g). The mixture was stirred and cooled the mixture was cooled, and the desired product purified by distillation to give butyl 2,2-difluorocyclopropane-1-carboxylate as a solution in anisole. This solution was added to a solution of aqueous NaOH and the biphasic mixture heated to 40° C. The mixture was cooled and filtered through Celite™ and layers were separated., The aqueous layer was washed with MTBE, acidified to pH 1-2, and washed twice with MTBE. The combined organic phases were distilled to solvent swap to MeCN to give 2,2-difluorocyclopropane-1-carboxylic acid as a solution in MeCN. To this solution was added chiral amine (R)-N-benzyl-1-phenylethan-1-amine and the mixture was heated to 40° , MTBE was added, and the mixture was cooled to 10° C. leading to crystallization of the desired 2,2-difluorocyclopropane-1-(S)-carboxylate (R)-N-benzyl-1-phenylethan-1-aminium salt. The solids were isolated by filtration and recrystallized from MeCN to give the material containing NMT 0.5% of the desired acid enantiomer.
Alternate Procedure: (R)-N-Benzyl-1-phenylethan-1-amine (S)-2,2-difluorocycloprop-ane-1-carboxylate. To a preheated eutectic mixture of 26.5% m/m biphenyl in diphenyl ether (1497 g) at 130° C. was added a solution of tetrabutylammonium bromide (6.8 g), butyl acrylate (1615 g), ethyl bromodifluoroacetate (853 g), in a eutectic mixture of biphenyl in diphenyl ether (748 g) and the mixture was maintained at 130-135° C. Additional tetrabutylammonium bromide (6.8 g) is added. The reaction is cooled, and 1,2-dichlorobenzene (1976 g) is added, and the mixture was distilled to provide the desired butyl 2,2-difluorocyclopropane-1-carboxylate as a solution in 1,2-dichlorobenzene. To this solution is added tetrabutylammonium bromide (5 mol %) and aqueous NaOH (4 equiv of 15% m/m) and the biphasic mixture stirred at room temperature. Additional tetrabutylammonium bromide is added (1.25 mol %). The phases are separated, and the aqueous phase is washed with MTBE and acidified to pH 1 with aqueous HCl, and extracted twice with MTBE. The combined organic phases are solvent swapped to MeCN to yield a 15% m/m solution of 2,2-difluorocyclopropane-1-carboxylic acid. The solution is heated to 40° C. and (R)- (+)-N-benzyl-1-phenylethan-1-amine (1.1 equiv) is added. The reaction is then further heated to 80° C., and the reaction mixture is seeded to promote crystallization of the title salt and cooled. The solids are isolated by filtration, washed with MeCN, and recrystallized using MeCN to give the desired material containing NMT 0.5% of the undesired acid enantiomer.
Alternate Procedure: (R)-N-Benzyl-1-phenylethan-1-amine (S)-2,2-difluorocycloprop-ane-1-carboxylate. To a solution of allyl hexanoate (225 L, 1.28 mol) in anisole (400 L) at 130° C. is added a mixture of ethyl bromodifluoroacetate (328 L, 2.56 mol) and tetrabutylammonium bromide (2.06 L, 0.006 mol) gradually. Additional portion of EBDFA (82.1 L, 0.64 mol) and tetrabutylammonium bromide (2.00 L, 0.006 mol) are added until full conversion of the allyl hexanoate is observed. The mixture is cooled, THF (1600 L) added, and the THF distilled from the system to remove any volatile by-products and give (2,2-difluorocyclopropyl)methyl hexanoate as a solution in anisole. To this solution is added aqueous KOH (301 L of 48 wt % KOH in 470 L of H2O ) and the mixture heated to 60° C. 0.5 wt % K2HPO4 (100 L) is added and the layers are separated. The aqueous layer is washed twice with methylene chloride (600 mL, each). To the combined organic layers is added TEMPO (9.94 g, 0.064 mol), potassium bromide (75.7 g, 0.636 mol), sodium bicarbonate (506.7 g, 6.03 mol), tetrabutylammonium bromide (20.51 L, 0.064 mol), and water (397.6 L) to forma a biphasic mixture. The reaction mixture is cooled to 10° C. and 14.8 wt % NaOCl (1777.5 L, 4.07 mol) is added. Sodium thiosulfate (100.6 g, 0.636 mol) is added, the solids are removed by filtration, and the cake is rinsed with methylene chloride (179 L). The layers are separated, and the organic layer is washed with aqueous NaOH (4.51 L of 30% NaOH in 795 L of H2O). The pH of the aqueous layer is adjusted with HCl to pH 2 and extracted twice with methylene chloride (596 L, each). The aqueous layer is washed with methyl tert-butyl ether twice (600 L, each). The solvent is swapped to give a solution of 2,2-difluorocyclopropane-1-carboxylic acid in acetonitrile. To this solution is added chiral amine (R)-N-benzyl-1-phenylethan-1-amine, and the reaction is stirred at 40° C. and then cooled to 20° C. which leads to crystallization of the title salt. The solids are collected by filtration, washed twice with MeCN, and then recrystallized in MeCN to give the title salt containing NMT 0.5% of the undesired acid enantiomer.
((S)-2,2-Difluorocyclopropyl)-((1R,5S)-3-(2-(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone p-Tosylate.
(R)-N-Benzyl-1-phenylethan-1-amine (S)-2,2-difluorocyclopropane-1-carboxylate (65.7 g, 197 mmol) is slurried in methyl t-butyl ether (441 mL) at 25° C. and treated with aqueous sulfuric acid (22 g, 217 mmol, 1.375 equiv). The phases are separated, the aqueous phase washed with methyl t-butyl ether (189 mL) and the organic phases combined. The combined organic phases are concentrated, tetrahydrofuran (THF) (550 mL) is added and the solution concentrated. A second addition of tetrahydrofuran (550 mL) and concentration is performed.
The solution of (S)-2,2-difluorocyclopropane-1-carboxylate in THF (approximately 430 mL) is cooled to 0° C. and 1,1′-carbonyldiimidazole (CDI) (36.9 g, 205 mmol, 1.3 equiv). Water (22.5 g) is then added. 2-Hydroxypyridine n-oxide (HOPO) (0.9 g, 7.9 mmol, 0.05 equiv) and 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (45 g, 158 mmol) are added at 0° C. until reaction is complete. The mixture is then warmed to 55° C. To the reaction is added a solution of p-toluenesulfonic acid monohydrate (52.8 g, 278 mmol, 1.75 equiv) in THF (99 mL). The solution is seeded with the title compound salt. A second portion of p-toluenesulfonic acid monohydrate (79.2 g, 416 mmol, 2.25 equiv) in THF (148 mL) is added over 4 hours. The slurry is then cooled to 10° C. The solid title compound salt is recovered by filtration, washed twice with a pre-mixed solution of 95:5 v/v
THF/water (5 volumes), then dried at 50+/−5° C. under vacuum. The title compound salt is isolated as a white crystalline solid (79.8 g, 90%).
Alternate Procedure: ((S)-2,2-Difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone p-Tosylate. Chiral 2,2-difluorocyclopropane-1-(S)-carboxylic acid was prepared by salt break of 2,2-difluorocyclopropane-1-(S)-carboxylate (R)-N-Benzyl-1-phenylethan-1-aminium salt. The acid chloride was prepared and reacted with isoquinolin-3-ol to afford isoquinolin-3-yl (S)-2,2-difluorocyclopropane-1-carboxylate. 1H NMR (400 MHz, DMSO) δ 9.23 (s, 1H), 8.20 (d, J=8.3 Hz, 1H), 8.02 (d, J=8.3 Hz, 1H), 7.83 (dd, J=8.4, 6.8 Hz, 1H), 7.75-7.66 (m, 2H), 3.22 (ddd, J=12.3, 10.9, 7.9 Hz, 1H), 2.35-2.13 (m, 2H). 13 C NMR (101 MHz, DMSO) δ 165.8, 153.5, 152.4, 138.3, 131.8, 128.2, 127.9 (d, J=2.6 Hz), 127.8, 126.9, 115.07, 112.2, 112.2 (dd, J=286.3, 284.4 Hz), 111.2, 109.3, 31.7, 28.8, 25.5, 25.4 (dd, J=12.8, 10.1 Hz), 25.3, 25.2, 17.4, 17.3 (t, J=10.0 Hz), 17.2.
4-((1R,5S)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (1.50 g, 5.26 mmol) is combined with tetrahydrofuran (21.4 mL) and water (1.13 mL). To the reaction is added isoquinolin-3-yl (S)-2,2-difluorocyclopropane-1-carboxylate (1.57 g, 6.30 mmol) and 2-hydroxypyridine N-oxide (0.029 g, 0.26 mmol). The reaction is stirred at room temperature until reaction is complete. The solution is heated to 50° C. p-Toluenesulfonic acid monohydrate (2.44 g, 12.6 mmol) was dissolved in tetrahydrofuran (7.13 mL) and water (0.375 mL). Approximately 1.7 mL of this solution is added to the reaction. The reaction may be seeded. The remaining acid solution is added. The slurry is cooled to room temperature. The solids are isolated by filtration, washing with THF/water. The title compound salt is isolated as a white crystalline solid (2.72 g). 1H NMR (400 MHz, DMSO) δ 9.23 (s, 1H), 8.20 (d, J=8.3 Hz, 1H), 8.02 (d, J=8.3 Hz, 1H), 7.83 (dd, J=8.4, 6.8 Hz, 1H), 7.75-7.66 (m, 2H), 3.22 (ddd, J=12.3, 10.9, 7.9 Hz, 1H), 2.35-2.13 (m, 2H). 13 C NMR (101 MHz, DMSO) δ 165.8, 153.5, 152.4, 138.3, 131.8, 128.2, 127.9 (d, J=2.6 Hz), 127.8, 126.9, 115.07, 112.2, 112.2 (dd, J=286.3, 284.4 Hz), 111.2, 109.3, 31.7, 28.8, 25.5, 25.4 (dd, J=12.8, 10.1 Hz), 25.3, 25.2, 17.4, 17.3 (t, J=10.0 Hz), 17.2. mp: 99.3° C.
Alternate Procedure: ((S)-2,2-Difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone p-Tosylate.
A reactor is charged with title compound salt (20.0 g, 35 mmol) and methyl isobutylketone (MIBK) (160 mL). A solution of sodium carbonate (4.52 g, 42 mmol, 1.2 equiv) in water (55 mL) is added. The reaction is stirred until a homogenous biphasic mixture is obtained. The aqueous layer is separated and back extracted with MIBK (100 mL). The organic phases are combined and washed with water (55 mL). The organic phase is concentrated to a volume of 100 mL. The solution is heated to 85° C. and heptane (67 mL) is added. The solution may be seeded. The solution is cooled to 25° C. The solids are isolated by filtration and washed with 30% heptane in MIBK. The title compound salt is isolated as a white crystalline solid.
1-Methyl-1H-pyrazol-4-amine Hydrochloride
To a 100 mL vessel containing a reflux condenser, temperature probe, and overhead stirrer was added 4-bromo-1-methyl-1H-pyrazole (7.0 g), acetamide (7.47 g, 3 equivs), K2CO3 (8.83 g, 1.5 equivs), ligand, and 2-methyl-2-butanol (70.0 mL) to give a yellowish slurry. Mixture was sparged with nitrogen for ˜20 minutes to remove oxygen. The vessel was then evacuated and backfilled with nitrogen a total of three times. With a strong sweep of nitrogen, the Cul was added, and the vessel heated to an internal temperature of 100° C. After 26 hours, the reaction cooled to 25° C. The reaction was diluted with a pre-mixed solution of sodium citrate (31.0 g, 2.5 equivs) in water (70 mL), which caused all solids to dissolve.
The layers were allowed to settle and the bottom (aqueous) layer removed. The resulting organic layer was extracted again with a pre-mixed solution containing sodium citrate (49.6 g, 4 equivs) in water (70 mL) and the layers separated. The resulting organic layer (˜90 mL) was concentrated distilled down under vacuum to ˜40mL, during which solid were observed to crystallize in the vessel, and then toluene (75 mL) added. This organic solution was further concentrated down (from ˜115 mL to ˜60 mL) and then the mixture cooled to 20° C., filtered and dried under vacuum at 50° C. N-(1-Methyl-1H-pyrazol-4-yl)acetamide was isolated as a light gray to tan solid. 1H NMR (400 MHz, DMSO) δ 9.89 (s, 1H), 7.84 (s, 1H), 7.36 (s, 1H), 3.77 (s, 3H), 1.97 (s, 3H). 13 C NMR (101 MHz, DMSO) δ 166.9, 129.8, 122.2, 121.5, 39.0, 23.2. mp: 149.0° C.
To a 50mL vessel topped with a reflux condenser, temperature probe, and overhead stirrer was added N-(1-methyl-1H-pyrazol-4-yl)acetamide (3.97 g), followed by 1-BuOH (32.0 mL), water (2.0 mL), and 12 M HCl (2.60 mL, 1.2 equivs). A slight exotherm was observed during addition of HCl. The mixture is heated to an internal temperature of 80° C. and held until full conversion of the starting material is observed (typically within 16-24 hours). The reaction mixture is concentrated via distillation to remove water, during which the desired product PF-05602633-01 is observed to crystallize as shimmery, white flakes. The slurry in cooled down to 20° C., the product isolated via filtration, washed with 1-BuOH and dried under vacuum at 50° C.
(S)-2,2-Difluorocyclopropane-1-carboxylic acid 2,2′,2″-nitrilotris(ethan-1-ol) salt.
To a 100 mL reactor was added MeCN (50.0 mL) and triethanolamine (12.2 g, 1.0 equivs). This solution was heated to 45° C., and a pre-mixed solution of 2,2-difluorocyclopropane-1-carboxylic (10.1 g, 1.0 equiv) in MTBE (50.0 mL, ˜20% w/w) was added dropwise over 100 minutes. After ˜40% of the MTBE solution had been added, the reaction was seeded with (S)-2,2-difluorocyclopropane-1-carboxylic acid 2,2′,2″-nitrilotris(ethan-1-ol) salt (42 mg, 0.002 equivs). After addition, the reaction was held at 45° C. for minutes, then cooled to 20° C. at a rate of 0.25° C./min. The mixture was granulated for 30 minutes, then filtered and washed with MTBE (40.0 mL), and dried under vacuum at 50° C. The difluoroacid can then be resolved through crystallization of the diastereomers. 1H NMR (400 MHz, DMSO) δ 6.85 (s, 4H), 3.61 (t, J=5.7 Hz, 6H), 2.97 (t, J=5.7 Hz, 6H), 2.38 (ddd, J=15.4, 10.8, 7.9 Hz, 1H), 1.84-1.62 (m, 2H). 13C NMR (101 MHz, DMSO) δ 169.0, 115.9, 113.1 (dd, J=285.9, 281.2 Hz), 113.1, 110.3, 57.4, 56.5, 27.7, 27.6 (dd, J=12.0, 9.2 Hz), 27.6, 27.5, 16.2, 16.1 (t, J=9.8 Hz), 16.0. mp: 82.4° C.
The present application is a national phase application based on PCT Application No. PCT/IB2021/055854, filed Jun. 30, 2021, which claims priority based on U.S. Provisional Application No. 63/047,590, filed Jul. 2, 2020, the disclosures of which are incorporated herein by reference in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2021/055854 | 6/30/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63047590 | Jul 2020 | US |
